Work

Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease

Year: 2003
Type: article
Abstract: infusion of DFO.The data from the 5 patients who remained in the study, together with data from 7 additional cases, are shown in Table 1.We did not record any adverse events in the 7 new cases, after a median follow-up of 28 months.As regards the second group of 11 transfusionindependent patients, 3 patients (patient nos.16, 23, and 27) died due to progression/relapse of disease and 2 patients (patient nos.18 and 26), who are still alive, came out of the protocol because they restarted chemotherapy due to relapse of the hematologic malignancy.In the remaining 6 patients (patient nos.11, 13, 20, 21, 24, and 25), the twice-daily subcutaneous bolus injections of DFO normalized ferritin levels.In these patients, who did not require transfusions during the follow-up after chemotherapy, DFO bolus injections were stopped once normal ferritin levels had been reached.The ferritin levels were then monitored every 3 months.Patient number 20 (with spherocytosis and hereditary hemochromatosis) started a maintenance phlebotomy program with bolus injection of DFO due to an increase of serum ferritin levels (780 g/L).Although the newly reported cases further testify to the efficacy of this method, there are some concerns regarding the long-term tolerance of DFO bolus injections.In fact, examining the follow-up of the previously published cases, we found that 3 of the 8 patients who remained in the study did not tolerate the volume of the bolus injections, preferring the subcutaneous continuous infusion.The pharmaceutical company producing DFO recommends a 10% final concentration of the drug, because higher concentrations have been shown to be associated with a higher incidence of local reactions at the injection site. 10ong-term follow-up trials on larger populations of patients are needed in order to clarify the real incidence of adverse reactions in patients using twice-daily subcutaneous bolus injections of deferoxamine.
Source: Blood
Language: English
Subfield: Ophthalmology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2068781069
FWCI: 3.528
Cites: 15
Cited by: 45
Related to: 10